Journal of Neuro-Oncology

, Volume 80, Issue 1, pp 27–35 | Cite as

Validation of the M.D. Anderson Symptom Inventory Brain Tumor Module (MDASI-BT)

  • T.S. Armstrong
  • T. Mendoza
  • I. Gring
  • C. Coco
  • M.Z. Cohen
  • L. Eriksen
  • Ming-Ann Hsu
  • M.R. Gilbert
  • C. Cleeland
Clinical Study

Summary

Background

Symptom occurrence has been shown to predict treatment course and survival in patients with solid tumors. Primary brain tumor (PBT) patients are unique in the occurrence of neurologic symptoms. Currently, no instrument exists that measures both neurologic and cancer-related symptoms.

Methods

Patients diagnosed with PBT participated in this study. Data was collected at one point in time and included demographic and clinical factors, and the M.D. Anderson Symptom Inventory-Brain Tumor Module (MDASI-BT). The study evaluated the reliability and validity of the MDASI-BT in primary brain tumor patients.

Results

Two hundred and one patients participated in this study. Mean symptom severity of items as well as cluster analysis was used to reduce the number of total items to 22 (13 core, 9 brain tumor items). Regression analysis showed more than half (56%) of the variability in symptom severity was explained by brain module items. The MDASI-BT measures six underlying constructs including affective, cognitive, focal neurologic deficit, constitutional, generalized symptom, and a gastrointestinal related factor. The internal consistency (reliability) of the instrument was 0.91. The MDASI-BT was sensitive to disease severity based on performance status (P<0.001), tumor recurrence (P<0.01), and mean symptom interference (P<0.001).

Conclusions

The 22 item MDASI-BT demonstrated validity and reliability in patients with PBT. This instrument can be used to identify symptom occurrence throughout the disease trajectory and to evaluate interventions designed for symptom management.

Keywords

brain tumors self-report instruments symptoms 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Notes

Acknowledgement

This study was supported by the Oncology Nursing Society/American Brain Tumor Association Neuro-oncology Research Grant and a grant from Pfizer Pharmaceuticals.

References

  1. 1.
    Armstrong T, Gilbert M Glial neoplasms: classification, treatment, and pathways for the future. Oncol Nurs Forum 1996;23(4):615–625PubMedGoogle Scholar
  2. 2.
    Rabbit JE, Page MS Selected complications in neuro-oncology patients. Semin Oncol Nurs 1998;14(1):53–60CrossRefPubMedGoogle Scholar
  3. 3.
    Fobair P, Mackworth N, Varghese A, Prados M: Quality of life issues among 200 brain tumor patients treated at the University of California in San Francisco, interviewed 1988. Presented at the Brain Tumor Conference: a living resource guide. San Francisco, California, March 3–5, 1990Google Scholar
  4. 4.
    Cimprich B Pretreatment symptom distress in women newly diagnosed with breast cancer. Cancer Nurs 1999;22(3):185–i94 quiz 95CrossRefPubMedGoogle Scholar
  5. 5.
    Degner LF, Sloan JA Symptom distress in newly diagnosed ambulatory cancer patients and as a predictor of survival in lung cancer. J Pain Symptom Manage 1995;10(6):423–431CrossRefPubMedGoogle Scholar
  6. 6.
    Graydon JE, Ross E Influence of symptoms, lung function, mood, and social support on level of functioning of patients with COPD. Res Nurs Health 1995;18(6):525–533PubMedGoogle Scholar
  7. 7.
    McCorkle M, Quint-Benoliel J Symptom distress, current concerns and mood disturbance after diagnosis of life-threatening disease. Soc Sci Med 1983;17(7):431–438CrossRefPubMedGoogle Scholar
  8. 8.
    Tamburini M, Brunelli C, Rosso S, Ventafridda V Prognostic value of quality of life scores in terminal cancer patients. J Pain Symptom Manage 1996;11(1):32–41CrossRefPubMedGoogle Scholar
  9. 9.
    Dodd M, Janson S, Facione N, Faucett J, Froelicher ES, Humphreys J, Lee K, Miaskowski C, Puntillo R, Rankin S, Taylor D Advancing the science of symptom management. J Adv Nurs 2001;33(5):668–676CrossRefPubMedGoogle Scholar
  10. 10.
    Lenz ER, Pugh LC, Milligan RA, Gift A, Suppe F The middle-range theory of unpleasant symptoms: an update. Adv Nurs Sci 1997;19(3):14–27Google Scholar
  11. 11.
    Clark JA, Talcott JA Symptom indexes to assess outcomes of treatment for early prostate cancer. Med Care 2001;39(10):1118–1130CrossRefPubMedGoogle Scholar
  12. 12.
    Sarna L Effectiveness of structured nursing assessment of symptom distress in advanced lung cancer. Oncol Nurs Forum 1998;25(6):1041–1048PubMedGoogle Scholar
  13. 13.
    Armstrong TS Symptoms experience: a concept analysis. Oncol Nurs Forum 2003;30(4):601–606PubMedGoogle Scholar
  14. 14.
    Dodd MJ, Miaskowski C, Paul SM Symptom clusters and their effect on the functional status of patients with cancer. Oncol Nurs Forum 2001;28(3):465–470PubMedGoogle Scholar
  15. 15.
    Chang VT, Hwang SS, Feurman M, Kasimis BS Symptom and quality of life survey of medical oncology patients at a Veteran Affairs medical center: a role for symptom assessment. Cancer 2000;88(5):1175–1183CrossRefPubMedGoogle Scholar
  16. 16.
    Portenoy RK, Thaler HT, Kornblith AB, Lepore JM, Friedlander-Klar K, Coyle N, Smart-Curley T, Kemeny N, Norton L, Hoskins W:Symptom prevalence, characteristics, and distress in a cancer population. Qual Life Res 1994;3(3):183–189CrossRefPubMedGoogle Scholar
  17. 17.
    Devito AJ Dyspnea during hospitalizations for acute phase of illness as recalled by patients with chronic obstructive pulmonary disease. Heart Lung 1990;19:186–191PubMedGoogle Scholar
  18. 18.
    Armstrong TS, Cohen MZ, Eriksen LR, Hickey JV Symptom clusters in oncology patients and implications for symptom research in people with primary brain tumors. J Nurs Scholarsh 2004;36(3):197–206CrossRefPubMedGoogle Scholar
  19. 19.
    Kayl AE, Meyers CA Does brain tumor histology influence cognitive function?Neuro-oncol 2003;5(4):255–260CrossRefPubMedGoogle Scholar
  20. 20.
    Salmaggi A, Riva M, Silvani A, Merli R, Tomei G, Lorusso L, et al. A multicentre prospective collection of newly diagnosed glioblastoma patients in Lombardia, Italy. Neurol Sci 2005;26(4):227–234CrossRefPubMedGoogle Scholar
  21. 21.
    Lovely MP, Miakowski C, Doss M Relationship between fatigue and quality of life in patients with glioblastoma multiforme. Oncol Nurs Forum 1999;26(5):921–925PubMedGoogle Scholar
  22. 22.
    Vazquez-Barquero A, Ibanez FJ, Herrera S, Izquierdo JM, Berciano J, Pascual J Isolated headache as the presenting clinical manifestation of intracranial tumors: a prospective study. Cephalalgia 1994;14(4):270–272CrossRefPubMedGoogle Scholar
  23. 23.
    McKeran RO, Thomas DGT: The clinical study of glioma. In: Thomas DGT, Graham DL., ed. Brain Tumors: Scientific Basis: Clinical Investigation and Current Therapy Lippincott Baltimore 1980:194–230Google Scholar
  24. 24.
    Jelsma R, Busy PC The treatment of glioblastoma multiforme of the brain. J Neurosurg 1967;27(5):388–400PubMedGoogle Scholar
  25. 25.
    Frankel SA, German WJ Glioblastoma multiforme: review fo 219 cases with regard to natural history, pathology, diagnostic methods, and treatment. J Neurosurg 1958;15:489–503PubMedGoogle Scholar
  26. 26.
    Roth JG, Elvidge AR Glioblastoma multiforme: a clinical survey J Neurosurg 1960;17:736–750PubMedCrossRefGoogle Scholar
  27. 27.
    Mukand JA, Blackinton DD, Crincoli M, Lee JJ, Santos BB Incidence of neurologic deficits and rehabilitation of patients with brain tumors. Am J Phys Med Rehab 2001;80(5):346–350CrossRefGoogle Scholar
  28. 28.
    Cleeland CS, Mendoza TR, Wang XS, Chou C, Harle MT, Morrissey M, Engstrom MC Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory. Cancer 2000;89(7):1634–1646CrossRefPubMedGoogle Scholar
  29. 29.
    Dropcho E, Soong S Steroid-induced weakness in patients with primary brain tumors. Neurology 1991;41:1235–1239PubMedGoogle Scholar
  30. 30.
    Gilbert M, Armstrong T, Meyers C Issues in assessing and interpreting quality of life in patients with malignant glioma. Semin Oncol 2000;27(3 Suppl 6):20–26PubMedGoogle Scholar
  31. 31.
    Weitzner MA, Meyers CA, Gelke CK, Byrne KS, Cella DF, Levin VA The Functional Assessment of Cancer Therapy (FACT) scale. Development of a brain subscale and revalidation of the general version (FACT-G) in patients with primary brain tumors. Cancer 1995;75(5):1151–1161PubMedCrossRefGoogle Scholar
  32. 32.
    Osoba D, Aaronson NK, Muller M, Sneeuw K, Hsu MA, Yung WK, et al. The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer-specific questionnaires Qual Life Res 1996;5(1):139–150CrossRefPubMedGoogle Scholar
  33. 33.
    Efficace F, Bottomley A Health related quality of life assessment methodology and reported outcomes in randomised controlled trials of primary brain cancer patients. Eur J Cancer 2002;38(14):1824–1831CrossRefPubMedGoogle Scholar
  34. 34.
    Cleeland CS, Reyes-Gibby CC When is it justified to treat symptoms? Measuring symptom burden. Oncology (Williston Park) 2002;16(9 Suppl 10):64–70Google Scholar
  35. 35.
    Walker M, Brown J, Brown K, Gregor A, Whittle IR, Grant R Practical problems with the collection and interpretation of serial quality of life assessments in patients with malignant glioma. J Neurooncol 2003;63(2):179–186CrossRefPubMedGoogle Scholar
  36. 36.
    Goodwin PJ, Black JT, Bordeleau LJ, Ganz PA Health-related quality-of-life measurement in randomized clinical trials in breast cancer-taking stock. J Natl Cancer Inst 2003;95(4):263–281PubMedCrossRefGoogle Scholar
  37. 37.
    Stone AA, Schwartz JE, Broderick JE, Shiffman SS Variability of momentary pain predicts recall of weekly pain: a consequence of the peak (or salience) memory heuristic. Pers Soc Psychol Bull 2005;31(10):1340–1346CrossRefPubMedGoogle Scholar
  38. 38.
    Armstrong TS, Cohen MZ, Eriksen L, Cleeland C Content validity of self-report measurement instruments: an illustration from the development of the Brain Tumor Module of the M.D. Anderson Symptom Inventory. Oncol Nurs Forum 2005;32(3):669–676CrossRefPubMedGoogle Scholar
  39. 39.
    Lynn MR Determination and quantification of content validity. Nurs Res 1985;35(6):382–385Google Scholar
  40. 40.
    Mendoza TR, Wang XS, Cleeland CS, Morrissey M, Johnson BA, Wendt JK, et al. The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory. Cancer 1999;85(5):1186–1196CrossRefPubMedGoogle Scholar
  41. 41.
    Serlin RC, Mendoza TR, Nakamura Y, Edwards KR, Cleeland CS When is cancer pain mild moderate or severe? Pain 1995;61(2):277–284CrossRefPubMedGoogle Scholar
  42. 42.
    Aldenderfer MS, Blashfield RK Cluster Analysis. Sage Publications, London, 1984Google Scholar
  43. 43.
    Harman HH: Modern Factor Analysis, 2. University of Chicago Press Chicago, 1967Google Scholar
  44. 44.
    Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5(6):649–655PubMedGoogle Scholar
  45. 45.
    Scheibel RS, Meyers CA, Levin VA: Cognitive dysfunction following surgery for intracerebral glioma: influence of histopathology, lesion location, and treatment. J Neuro-Oncol 1996;30:61–69CrossRefGoogle Scholar
  46. 46.
    Meyers CA, Smith JA, Bezjak A, Mehta MP, Liebmann J, Illidge T, et al. Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial. J Clin Oncol 2004;22(1):157–165CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, Inc. 2006

Authors and Affiliations

  • T.S. Armstrong
    • 1
    • 2
    • 4
  • T. Mendoza
    • 2
  • I. Gring
    • 2
  • C. Coco
    • 2
  • M.Z. Cohen
    • 1
    • 2
  • L. Eriksen
    • 1
    • 2
  • Ming-Ann Hsu
    • 3
  • M.R. Gilbert
    • 2
  • C. Cleeland
    • 2
  1. 1.The University of Texas Health Science Center at Houston, School of NursingHoustonUSA
  2. 2.The University of Texas M.D. Anderson Cancer CenterHoustonUSA
  3. 3.Pfizer, Inc.New LondonUSA
  4. 4.Neuro-Oncology, Unit 431, UT MDACCHoustonUSA

Personalised recommendations